Indian Journal of Private Psychiatry

Register      Login

VOLUME 18 , ISSUE 2 ( July-December, 2024 ) > List of Articles

CASE REPORT

Endoxifen for the Management of Pathological Gambling in a Male Patient Who Overinvested in Cryptocurrency: A Case Report

Yamini Kannappan

Keywords : Case report, Endoxifen, Impulsivity, Pathological gambling, Protein kinase C

Citation Information : Kannappan Y. Endoxifen for the Management of Pathological Gambling in a Male Patient Who Overinvested in Cryptocurrency: A Case Report. Ind J Priv Psychiatry 2024; 18 (2):88-90.

DOI: 10.5005/jp-journals-10067-0184

License: CC BY-NC 4.0

Published Online: 26-07-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Gambling is a high-risk activity that can be addictive and has both financial and personal repercussions. There is an association between gambling risk and intensive engagement in cryptocurrency trading. The management of gambling disorder has relied on medications including naltrexone and selective serotonin reuptake inhibitors (SSRIs), which have certain limitations including adverse effects and the need for longer treatment, respectively. This case report describes the use of adjunctive endoxifen in a male patient who had overinvested in cryptocurrency. The patient had used his own funds and had borrowed as well as stolen money for this purpose. The patient was counseled and treated with endoxifen, which successfully helped him overcome the habit of cryptocurrency gambling. Endoxifen is a protein kinase C (PKC) inhibitor and PKC overactivity leads to impulsivity. Hence, the use of endoxifen could be an effective strategy in the management of gambling disorders. Larger studies exploring this approach are needed.


HTML PDF Share
  1. Delfabbro P, King D, Williams J, et al. Cryptocurrency trading, gambling and problem gambling. Addictive Behav 2021;122:107021. DOI: 10.1016/j.addbeh.2021.107021.
  2. Arthur JN, Williams RJ, Delfabbro PH. The conceptual and empirical relationship between gambling, investing, and speculation. J Behav Addict 2016;5(4):580–591. DOI: 10.1556/2006.5.2016.084.
  3. Kim SW, Grant JE, Potenza MN, et al. The Gambling Symptom Assessment Scale (G-SAS): A reliability and validity study. Psychiatry Res 2009;166(1):76–84. DOI: 10.1016/j.psychres.2007.11.008.
  4. Ioannidis K, Hook R, Wickham K, et al. Impulsivity in gambling disorder and problem gambling: A meta-analysis. Neuropsychopharmacology 2019;44(8):1354–1361. DOI: 10.1038/s41386-019-0393-9.
  5. Birnbaum SG, Yuan PX, Wang M, et al. Protein kinase C overactivity impairs prefrontal cortical regulation of working memory. Science 2004;306(5697):882–884. DOI: 10.1126/science.1100021.
  6. Ahmad A, Sheikh S, Khan MA, et al. Endoxifen: A new, protein kinase C inhibitor to treat acute and mixed mania associated with bipolar I disorder. Bipolar Disord 2021;23(6):595–603. DOI: 10.1111/bdi.13041.
  7. Ali SM, Ahmad A, Shahabuddin S, et al. Endoxifen is a new potent inhibitor of PKC: A potential therapeutic agent for bipolar disorder. Bioorg Med Chem Lett 2010;20:2665–2667. DOI: 10.1016/j.bmcl.2010.02.024.
  8. Choi SW, Shin YC, Kim DJ, et al. Treatment modalities for patients with gambling disorder. Ann Gen Psychiatry 2017;16:23. DOI: 10.1186/s12991-017-0146-2.
  9. Kulkarni YA. Management approach to a patient with borderline personality disorder, trichotillomania, and alcohol dependence syndrome: Use of endoxifen. Int Multispecialy J Health 2024;10(3): 1–4. DOI: 10.5281/zenodo.10899861.
  10. Dave M, Shanmugasundaram N. Endoxifen for the management of bipolar disorder with comorbid substance use disorder: A report of two cases. Arch Biol Psychiatr 2023;1(1):25–28. DOI: 10.25259/ABP_1_2023.
  11. Banerjee D, Ray R. Endoxifen in treatment of individuals with borderline personality disorder with predominant impulsivity: A case series. Consort Psychiatri 2023;4(4):CP13622. DOI: 10.17816/CP13622.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.